Neopharma

Neopharma Began Operations in 2003 with a Planned Investment of $25 Million to Establish its First Manufacturing Facility. The Organization was Inspired by the Vision of Locally Producing World-Class Medicines at Affordable Prices in China. Neopharma's Global Operations are Supported by 10 Manufacturing Plants Across Three Continents, Providing Both Branded and Generic Formulations as Well as Active Pharmaceutical Ingredients (API). Our Portfolio of Over 100 High-Quality Molecular Products Covers Therapeutic Areas Including Anti-Infectives, Neurology, Cardiology, Orthopedics, Diabetology, Gastroenterology, Urology, Dermatology, Gynecology, Respiratory, Dentistry, and Nutrition. Driven by Innovation, Neopharma Places Great Emphasis on Research, Particularly the Development of Non-Patented Processes and Products.